Samsung C&T cuts Samsung Biologics rights issue indicative price to KRW 1,174,000 per share in correction filing

Bitget2026/10/01 09:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Samsung C&T corrected its disclosure on Samsung Biologics’ rights offering following confirmation of the first-stage offer price.
Proceeds earmarked for securities acquisitions were revised to KRW 2.66 trillion from KRW 2.71 trillion.
Indicative offer price for common shares was cut to KRW 1,174,000 from KRW 1,322,000.
Record date set for Oct. 6, 2026. Final offer price is due Nov. 4, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001800695), on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Samsung C&T cuts Samsung Biologics rights issue indicative price to KRW 1,174,000 per share in correction filing

You may also like

Crypto prices